Carole Ho Sells 3,689 Shares of Denali Therapeutics Inc (NASDAQ:DNLI) Stock

Denali Therapeutics Inc (NASDAQ:DNLI) insider Carole Ho sold 3,689 shares of Denali Therapeutics stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $31.00, for a total transaction of $114,359.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NASDAQ:DNLI opened at $37.27 on Wednesday. Denali Therapeutics Inc has a 12 month low of $12.39 and a 12 month high of $37.82. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.57 and a quick ratio of 9.57. The business’s 50 day simple moving average is $30.23 and its 200-day simple moving average is $24.42. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -17.33 and a beta of 1.91.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.05. Denali Therapeutics had a negative net margin of 778.32% and a negative return on equity of 45.90%. On average, equities analysts anticipate that Denali Therapeutics Inc will post 1.4 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in DNLI. Cutler Group LP increased its holdings in shares of Denali Therapeutics by 140.0% during the 2nd quarter. Cutler Group LP now owns 1,440 shares of the company’s stock worth $34,000 after purchasing an additional 840 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Denali Therapeutics during the first quarter worth approximately $26,000. Private Advisor Group LLC acquired a new position in shares of Denali Therapeutics during the second quarter worth approximately $47,000. Macquarie Group Ltd. bought a new stake in shares of Denali Therapeutics during the second quarter worth approximately $92,000. Finally, Bank of Montreal Can raised its stake in shares of Denali Therapeutics by 956.9% during the second quarter. Bank of Montreal Can now owns 5,031 shares of the company’s stock worth $135,000 after buying an additional 4,555 shares during the last quarter. Hedge funds and other institutional investors own 77.91% of the company’s stock.

DNLI has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Zacks Investment Research cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Morgan Stanley raised their price target on shares of Denali Therapeutics from $28.00 to $45.00 and gave the stock an “overweight” rating in a research report on Monday, August 24th. TheStreet raised shares of Denali Therapeutics from a “d+” rating to a “c-” rating in a report on Wednesday, May 20th. Finally, Wedbush reiterated an “outperform” rating on shares of Denali Therapeutics in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $33.36.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: VIX – Volatility Index

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.